Skip to main content

Table 4 Univariate analysis of time to progression (TTP) and overall survival (OS) using the Cox proportional hazard model

From: Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

 

n

TTP analysis

OS analysis

  

Hazard ratio (95% CI)

Log-rank

P -value

Hazard ratio (95% CI)

Log-rank P -value

Baseline characteristics

Age†

37

0.984 (0.944-1.02)

0.429

0.996 (0.962-1.03)

0.819

Sex (male vs. female)

37

(34 vs. 3)

0.214

(0.028-1.64)

0.105

0.654

(0.155-2.76)

0.559

Number of disease sites

(1 vs. ≥ 2)

37

(18 vs. 19)

1.78

(0.754-4.18)

0.183

1.03

(0.501-2.11)

0.939

Cirrhosis (no vs. yes)

35

(23 vs. 12)

2.22

(0.907-5.41)

0.0743

2.23

(0.975-5.11)

0.0521

Portal vein thrombosis

(no vs. yes)

37

(18 vs. 19)

1.3

(0.549-3.1)

0.547

2.00

(0.938-4.27)

0.0682

Hepatitis B (no vs. yes)

32

(15 vs. 7)

1.74

(0.685-4.4)

0.240

1.07

(0.489-2.35)

0.864

Histological grade

(low or medium vs. high)

33

(22 vs. 11)

0.756

(0.276-2.07)

0.586

0.78

(0.337-1.81)

0.561

Child-Pugh class (A vs. B)

37

(31 vs. 6)

1.49

(0.428-5.18)

0.530

3.39

(1.34-8.61)

0.0065*

ECOG PS (0 vs. 1)

37

(19 vs. 18)

3.21

(1.19-8.63)

0.0157*

7.86

(2.78-22.2)

< 0.0001*

CLIP stage (≤ 2 vs. > 2)

27

(15 vs. 12)

1.57

(0.490-5.00)

0.445

1.23

(0.54-2.81)

0.62

Soluble proteins

Baseline VEGF-A (ng/mL)†

37

0.041

(0.0006-3.00)

0.132

1.04

(0.056-19.4)

0.977

Baseline VEGF-C (ng/mL)†

37

0.413

(0.196-0.869)

0.0165*

0.683

(0.384-1.21)

0.190

Baseline sVEGFR-2 (ng/mL)†

37

0.887

(0.699-1.13)

0.325

0.969

(0.803-1.17)

0.746

Baseline sKIT (ng/mL)†

37

0.996

(0.959-1.04)

0.853

0.997

(0.970-1.02)

0.804

sVEGFR-2 ratio to baseline at C1D28†

28

0.216

(0.0084-5.54)

0.353

0.049

(0.0027-0.672)

0.0253*

  1. Hazard ratio < 1 indicates that risk decreases with increasing value
  2. *Significant at the 0.05 level
  3. †Analyzed as continuous variables
  4. CLIP, Cancer of the Liver Italian Program; ECOG PS, Eastern Cooperative Oncology Group performance status